Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:anticoagulantType |
gptkb:anticoagulant
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:ATCCode |
B01AF03
|
| gptkbp:brand |
gptkb:edoxaban
|
| gptkbp:contraindication |
active pathological bleeding
severe hepatic impairment |
| gptkbp:discoveredBy |
gptkb:Daiichi_Sankyo
|
| gptkbp:halfLife |
10-14 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lixiana
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Daiichi_Sankyo
|
| gptkbp:mechanismOfAction |
factor Xa inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
bleeding |
| gptkbp:usedFor |
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis treatment of pulmonary embolism |
| gptkbp:bfsParent |
gptkb:edoxaban
|
| gptkbp:bfsLayer |
6
|